Skip to main content

Table 1 Demographic and Clinical Characteristics of the 246 patients, Stratified by AKI

From: Association of overweight with postoperative acute kidney injury among patients receiving orthotopic liver transplantation: an observational cohort study

Cohort CharacteristicsAKI, No. (%)P Value
Yes (n = 163)No (n = 81)
Age, mean (SD), y54.8 (9.6)53.2 (9.7)0.281
Female, No. (%)31 (19.0)8 (9.9)0.066
BMI, median (IQR), kg/m224.7 (22.5–27.1)23.0 (20.8–25.6)0.004
Personal history
 Smoking, No. (%)59 (37.1)29 (37.7)0.934
 Alcoholism, No. (%)59 (37.6)35 (46.1)0.216
Comorbidities
 Hypertension, No. (%)44 (27.0)25 (30.9)0.527
 Diabetes mellitus, No. (%)58 (35.6)28 (34.6)0.876
 Chronic kidney disease, No. (%)20 (12.3)10 (12.3)0.986
 HBV, No. (%)78 (47.9)47 (58.0)0.134
 HCV, No. (%)6 (3.7)4 (4.9)0.641
 Encephalopathy, No. (%)11 (6.7)6 (7.4)0.849
 Ascites, No. (%)37 (22.7)18 (22.2)0.933
Underlying liver disease  0.356
 Hepatocellular carcinoma
+Viral hepatitis, No. (%)
65 (39.9)38 (46.9) 
 Hepatocellular carcinoma, No. (%)36 (22.1)12 (14.8) 
 Viral hepatitis, No. (%)32 (19.6)19 (23.5) 
 Alcohol-related liver disease, No. (%)11 (6.7)7 (8.6) 
 Other, No. (%)19 (11.7)5 (6.2) 
GFR, median (IQR)145.0 (108.4–186.3)134.5 (104.0–164.3)0.144
Child-Pugh score, median (IQR)8.0 (7.0–9.0)8.0 (7.0–9.0)0.268
MELD score, median (IQR)6.7 (0.5–12.5)7.2 (2.1–14.6)0.474
Preoperative laboratory data
 Creatinine, median (IQR), mg/dL65.0 (50.0–78.0)71.0 (64.0–88.0)< 0.001
 Sodium, median (IQR), mEq/L140.0 (138.0–142.0)140.0 (137.0–142.0)0.865
 Albumin, median (IQR), g/dL35.0 (30.6–39.7)35.3 (30.9–40.6)0.520
 Total bilirubin, median (IQR), umol/L49.1 (26.6–129.3)44.6 (20.9–397.0)0.568
 Glucose, median (IQR), mg/dL5.0 (4.4–6.4)5.2 (4.6–6.2)0.282
 Lactic acid, median (IQR), mmol/L1.2 (1.0–1.6)1.3 (1.1–1.8)0.092
Surgery
 Estimated blood loss, median (IQR), L2.0 (1.0–2.5)1.5 (0.8–2.1)0.146
 RBC transfusion, median (IQR), units12.0 (6.0–14.0)9.0 (4.0–13.5)0.026
 Nadir MAP, median (IQR), mmHg64.9 (61.7–68.5)64.9 (63.3–69.3)0.923
Requirement of vasopressors (large dose), No. (%)
 Duration of surgery, median (IQR), min531.0 (468.0–572.0)531.0 (470.0–570.0)0.811
 Cold ischemia time, median (IQR), min382.0 (326.0–384.0)383.0 (325.0–387.0)0.628
 Anhepatic phase, median (IQR), min60.0 (52.0–60.0)60.0 (56.0–64.0)0.128
Postoperative parameter
 Peak AST, median (IQR), U/L526.0 (72.5–795.5)285.0 (79.0–742.0)0.805
 Tacrolimus, median (IQR), ng/mL9.00 (6.65–11.50)8.30 (6.30–12.10)0.657
 Postoperative hospitalization, median (IQR), day27.0 (21.0–30.0)25.0 (20.0–28.0)0.334
 Hospital mortality, No. (%)5 (3.1)2 (2.5)1.000